- In late June 2026, H.B. Fuller reported stronger second-quarter and year-to-date results, with higher sales, net income, and earnings per share compared with the prior year, completed a US$134.32 million share repurchase program covering 2,134,937 shares, and faced pressure from Ancora Holdings Group, which threatened a proxy fight if governance and performance do not improve.
- The combination of improved profitability, capital returned through buybacks, and public investor activism highlights how both internal execution and external pressure are shaping expectations for H.B. Fuller’s future governance and capital allocation choices.
- We’ll now examine how H.B. Fuller’s stronger quarterly earnings performance could influence its existing investment narrative and outlook assumptions.
Explore 27 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
H.B. Fuller Investment Narrative Recap
To own H.B. Fuller, you need to be comfortable with a steady, margin-focused adhesives business while keeping an eye on debt levels and cyclical end markets. The latest quarter’s stronger earnings support the view that portfolio and pricing initiatives are gaining traction in the near term, but Ancora’s threat of a proxy fight brings governance and capital allocation under closer scrutiny. For now, the main near term catalyst remains execution on margin improvement, while leverage and potential governance instability stand out as key risks.
The completion of the US$134.32 million share repurchase program, covering 2,134,937 shares, is especially relevant here, as it sits at the intersection of capital returns, balance sheet flexibility, and Ancora’s governance concerns. While these buybacks can support earnings per share by lowering share count, investors may now pay closer attention to how further cash flows are balanced between dividends, debt reduction, and any future repurchases, given prior worries about H.B. Fuller’s elevated net debt to EBITDA ratio.
Yet behind the stronger quarter and completed buyback, investors should still be aware of the company’s relatively high net debt levels and...
Read the full narrative on H.B. Fuller (it's free!)
H.B. Fuller’s narrative projects $4.3 billion revenue and $248.3 million earnings by 2029.
Uncover how H.B. Fuller's forecasts yield a $73.29 fair value, a 26% upside to its current price.
Exploring Other Perspectives
Two fair value estimates from the Simply Wall St Community span roughly US$73 to US$93 per share, underscoring how differently individuals can view the same business. Set against concerns about H.B. Fuller’s higher net debt to EBITDA ratio, this spread shows why it can help to compare several independent views before forming your own.
Explore 2 other fair value estimates on H.B. Fuller - why the stock might be worth as much as 61% more than the current price!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your H.B. Fuller research is our analysis highlighting 6 key rewards and 1 important warning sign that could impact your investment decision.
- Our free H.B. Fuller research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate H.B. Fuller's overall financial health at a glance.
Ready To Venture Into Other Investment Styles?
Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:
- We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Find 44 companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com